PHARMACOLOGY & THERAPEUTICS

Executive Editors
W. C. Bowman, A. M. Breckenridge, A. C. Sartorelli.

CHEMOTHERAPY

CLINICAL PHARMACOLOGY & THERAPEUTICS

TOXICOLOGY

METABOLIC INHIBITORS

GENERAL & SYSTEMATIC PHARMACOLOGY

OL.
25
984

Volume contents, Author index
and Subject index to
Volume 25

PERGAMON PRESS OXFORD NEW YORK

PHARMACOLOGY & THERAPEUTICS

Chemotherapy, Toxicology and Metabolic Inhibitors

Executive Editor: A. C. Sartorelli

Yale University School of Medicine, Department of Pharmacology, 333 *Cedar Street, New Haven, Connecticut* 06510, *USA*

Associate Editor: John S. Lazo

Managing Editor: Barbara Z. Renkin, Ph.D.

General and Systematic Pharmacology

Executive Editor: W. C. Bowman

University of Strathclyde, Department of Physiology & Pharmacology, Royal College, 204 *George Street, Glasgow G1 1XW, Scotland*

Clinical Pharmacology and Therapeutics

Executive Editor: A. M. Breckenridge

University of Liverpool, Department of Pharmacology & Therapeutics, P.O. Box 147, *Liverpool L69 3BX, England*

Editorial Board

G. E. Adams—*Sutton, Surrey, England*
S. Agoston—*Groningen, Netherlands*
Joseph R. Bertino—*New Haven, Connecticut*
Ernest Bueding—*Baltimore, Maryland*
B. A. Callingham—*Cambridge, England*
Donald S. Coffey—*Baltimore, Maryland*
William A. Creasey—*Philadelphia, Pennsylvania*
P. F. D'Arcy—*Belfast, N. Ireland*
M. A. Denborough—*Canberra, Australia*
Robert L. Dixon—*Washington DC*
Jürgen Drews—*Wien, Austria*
W. F. Dryden—*Edmonton, Alberta, Canada*
B. L. Furman—*Glasgow, Scotland*
George A. Galegov—*Moscow, USSR*
C. F. George—*Southampton, England*
Evgeny Golovinsky—*Sofia, Bulgaria*
Robert E. Handschumacher—*New Haven, Connecticut*
Peter Langen—*Berlin, GDR*
Åke Liljestrand—*Stockholm, Sweden*
Jerry Mitchell—*Houston, Texas*
A. Nies—*Denver, Colorado*
E. E. Ohnhaus—*Essen, German Federal Republic*
M. L'E. Orme—*Liverpool, England*
J. Gy Papp—*Szeged, Hungary*
Robert E. Parks, Jr.—*Providence, Rhode Island*
Sidney Pestka—*Nutley, New Jersey*
William H. Prusoff—*New Haven, Connecticut*
J. L. Reid—*Glasgow, Scotland*
A. Richens—*Cardiff, Wales*
D. S. Savage—*Glasgow, Scotland*
D. G. Shand—*Durham, North Carolina*
David Shugar—*Warsaw, Poland*
F. Sjöqvist—*Huddinge, Sweden*
Jan Škoda—*Prague, Czechoslovakia*
A. Stafford—*Glasgow, Scotland*
Donald J. Tipper—*Worcester, Massachusetts*
E. S. Vesell—*Hershey, Pennsylvania*
George Weber—*Indianapolis, Indiana*
Gerhard Zbinden—*Zürich, Switzerland*

Library Annual Subscription Rates—published in 4 volumes per annum of 3 issues each.
Annual Subscription, 1986, U.S. $800.00 including postage and insurance, 2 years, 1986/87, U.S. $1520.00.
Specially Reduced Rates to Individuals: Any individual whose institution takes out a library subscription may purchase a second or additional subscription for personal use at a much reduced rate of $350.00 annually. Subscribers to the Journal may claim a 20% discount off Encyclopedia volumes.

Subscription enquiries from customers in North America should be sent to Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523, USA, and for the remainder of the world to Pergamon Press Ltd, Headington Hill Hall, Oxford OX3 0BW, England.

At the end of the year, the Subscriber will receive, free, both the annual subject index and an attractive and durable magazine binder, especially designed for *Pharmacology & Therapeutics*.

Copyright © 1985 Pergamon Press Ltd.

It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright for their article is transferred to the publisher if and when the article is accepted for publication. However, assignment of copyright is not required from authors who work for organisations which do not permit such assignment. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproduction, microform or any other reproduction of similar nature and translations. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical photocopying recording or otherwise, without permission in writing from the copyright holder.

U.S. COPYRIGHT LAW APPLICABLE TO USERS IN THE U.S.A.

The Item-Fee Code for this publication indicates that authorization to photocopy items for internal or personal use is granted by the copyright holder for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service provided the stated fee for copying beyond that permitted by Section 107 or 108 of the United States Copyright Law is paid. The appropriate remittance of $0.50 per page is paid directly to the Copyright Clearance Center Inc., 21 Congress Street, Salem, MA 01970. The copyright owner's consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific written permission must be obtained from the publisher for such copying. In case of doubt please contact your nearest Pergamon Office.

The Item-Fee Code for this publication is: 0163 7258/84 $0.00 + 0.50

Microform Subscriptions and Back Issues

Back issues of all previously published volumes are available in the regular editions and on microfilm and microfiche. Current subscriptions are available on microfiche simultaneously with the paper edition and on microfilm on completion of the annual index at the end of the subscription year.

Publishing and Advertising Offices

Pergamon Press Ltd.
Headington Hill Hall
Oxford OX3 0BW
England

Pergamon Press Inc.
Maxwell House
Fairview Park, Elmsford
New York 10523, U.S.A.

Volume 25, 1984, Numbers 1–3

CONTENTS

Number 1 PAGE

Methods in testing interrelationships between excretion of drugs via urine and bile: *C. Fleck and H. Bräunlich* 1

The action of neurotransmitters and related substances on early embryogenesis: *G. A. Buznikov* 23

Biological effects of folic acid antagonists with antineoplastic activity: *R. C. Jackson* 61

Taxol: an antimitotic agent with a new mechanism of action: *J. J. Manfredi and S. B. Horwitz* 83

Number 2

The pharmacology and clinical uses of tamoxifen: *B. J. A. Furr and V. C. Jordan* 127

Cytosine arabinoside: molecular, pharmacokinetic and cytokinetic considerations: *M. G. Pallavicini* 207

Recent studies on inhibitors of macromolecular synthesis and function in trypanosomes: *S. R. Meshnick* 239

Apamin: *E. Habermann* 255

Number 3

Calcium ions, drug action and the heart — with special reference to calcium antagonist drugs: *L. H. Opie* 271

cis-Diamminedichloroplatinum (II): effects of a representative metal coordination complex on mammalian cells: *E. B. Douple* 297

Biosynthesis of peptidoglycan: points of attack by wall inhibitors: *J. B. Ward* 327

Pharmacological aspects of mammalian hibernation: *C. P. Lyman* 371

Role of DNA lesions and repair in the transformation of human cells: *V. M. Maher and J. J. McCormick* 395

OL.
25
984

AUTHOR INDEX

Bräunlich, H. 1
Buznikov, G. A. 23

Douple, E. B. 297

Fleck, C. 1
Furr, B. J. A. 127

Habermann, E. 255
Horwitz, S. B. 83

Jackson, R. C. 61
Jordan, V. C. 127

Lyman, C. P. 371

Maher, V. M. 395
Manfredi, J. J. 83
McCormick, J. J. 395
Meshnik, S. R. 239

Opie, L. H. 271

Pallavicini, M. G. 207

Ward, J. B. 327

SUBJECT INDEX

Acetylcholine and sea urchin egg cleavage 40–3
Acriflavin, trypanocidal activity 241, 242
Adjuvant therapy, tumors and tamoxifen 179–81
Adverse drug reactions
  calcium antagonists 289, 290
  cis-DDP 310, 311
  tamoxifen 165–7, 174
Angina
  calcium antagonists 283, 284, 286
  and verapamil 283
Antiestrogen binding protein 139
Apamin 255–68
  ATP hyperpolarization 264
  autoradiographic localization 259
  binding 257–60
    data 258
  calcium-triggered potassium channel 266, 267
  carbachol contracted guinea-pig taenia coli response 264–6
  derivatives 260, 262, 263
    lethality 262, 263
    structures 263
  mechanism of action 266, 267
  nervous system effects 259–61
  peripheral organ effects 261
  poisoning symptoms 255–9
  sites 264
  spatial structure scheme 256, 257
  structure 255
  structure–activity relationship 257–60
  toxicity 260
Ara-C *see* cytosine arabinoside

Bee venom 255
Bis-C6-DHB and glutathione synthesis 250, 251
Buthionine sulfoxime and glutathione synthesis 250, 251

Calcium and sea urchin embryogenesis 42
Calcium antagonists 271–90 *see also* verapamil
  adrenoreceptor effects 273, 280, 282
  arterial calcinosis 283
  class B 287
  clinical indications 283–6
  clinical properties 286, 287
  contraindications 288, 300
  definition 271, 272
  drug interactions 287
  effects 272
  injury inhibition 281
  mode of action 273, 274
  nomenclature 271
  potency 280
  sarcolemma binding 272, 273
  side-effects 299, 300
  sites of action 278–81
  structure–activity relationship 273
  ventricular fibrillation 281, 282
Calcium channel
  calmodulin effects 277
  functionally different 276
  model 274–6
Calcium-triggered potassium channel, apamin mechanism 266, 267
Cells, fibroblast, neoplastic transformation 403, 404
Centrosomes, electron microscopy 89
Cytosine arabinoside (Ara-C) 207–33
  administration and treatment 207, 208
  cytometric perturbations 229–31
  DNA synthesis inhibition 210–12
  erythroid progenitors 225
  granulocyte progenitors 225
  haematopoietic system 222–6
    spleen colony assay 223
  high dose 218
  membrane precursors 212, 213
  metabolic pathways 209
  molecular perturbations 213, 214
  molecular structure 208
  multiple doses *in vivo* 217, 218
  pharmacokinetics 219–22
    normal cells 222
  pleuripotent stem cells 223–5
  research objectives 231–3
  resistance 210
  small intestine 226–31
    clonigenic crypt cell survival 227–9
    single and multi-dose 227–9
  S-phase cytotoxicity 214, 215
  toxicity and animal survival 233
  tumor effects 214–18
    dose-survival 215
    pharmacokinetics 220–2
    proliferation-dependent 215, 216
    unbalanced growth 217
Cytotoxic drugs, tamoxifen combination 176–8
Cytotoxicity and DNA repair effects 396–9
  doses of carcinogens 398

cis-Diamminedichloroplatinum (II) (*cis*-DDP)
  analogs 313–15
  aquation 298
  chemistry 297–9
  combination therapy 312, 313
    chemotherapy 306, 307
    hypothermia 309
    in vitro 306–9
    in vivo 309–13
    radiation 307–9
  cytotoxicity 303–6
  development of research 315–17
  DNA effects 299–302
  ELISA assay 300
  isomer structures 298
  guanine binding 300
  organelle effects 302, 303
  protein binding 302
Dihydrofolate reductase 65, 66
Diltiazem effects 272 *see also* calcium antagonists

DNA repair
carcinogen cytotoxicity 396–9
excision time and synthesis 401–3
transformation 404, 405
mutation frequency 399–401
transformation process 404
DNA synthesis, Ara-C inhibition 210–12
Drugs, biliary and renal excretion 213

Embryogenesis
acetylcholine role 40–3
blastomere uncoupling 45, 46
calcium ion effect 42
cell neurochemical responses 48, 49
cytostatic activity 34, 35
morphogenetic movements 47, 48
neurochemical sensitivity 31–40
neurotransmitters 23–52
lipid synthesis 44
macromolecular synthesis 43, 44
sea urchins 25–31
receptor lack 38
stages, sea urchin 32
Estrogen
subcellular effects 131
uterus effects and transformation 131
Excretion
animal experiments 13–15
biliary and renal
combined interference 14, 15
discrepancies 2, 3
biliary, biotransformation 12
interference 10–13
mechanisms 5, 6
renal
increasing 9
interference 7–9
mechanisms 4, 5

Folate deficiency 61
antifolate states 61–3
Folic acid antagonists 61 *see also* methotrexate
antineoplastic activity 63–5
cell cycle effects 68–74 *see also* methotrexate
biochemistry 72, 73
flow cytometry 73, 74
interconversion enzymes 65–8
nuclear structure 74, 75
organelle effects 74–6
plasma membrane effects 75
selectivity 67, 68
structure 64
Folic acid structure 64

Haematopoietic system, cytosine arabinoside effects 222–6
Heart failure, calcium antagonists 285, 286
Hibernation
acetylcholine role 381–4
ambient gases 380
arousal 372, 386–90
acetylcholine effects 388
CNS role 384, 385
drug effects 387
norepinephrine effects 388, 389
sensitivity 385, 386
sequence 386, 387
study 381
brain temperature alteration 379
brown fat and heart activity 375
deep 378–85
entering 372–8
homeostasis 372
metabolic heat production 376, 379
neurotransmitters 378, 379
norepinephrine turnover 375, 376
parasympathetic role in deep 382
polyphyletic 373
pulse pressure patterns 374
renal physiology 382
respiratory rate 380, 381
sleep changes 377
species studies 371
Hibernation induction trigger 377
5-Hydroxytryptamine (5-HT)
analog and protein synthesis 44
in hibernation 378, 379
sea urchin embryogenesis 26–30
cytostatic protection 36
indocarb effect 37

Inhibitors, *Trypanosoma* sp macromolecule synthesis 239–51

MCD peptide structures 255
Methotrexate, cell cycle effects 65–8
log phase 70
models 69, 70
phase specificity 70–2
Microtubule
assembly and taxol 83–91
centrosomes 89
depolymerization, calcium and colchicine 114
midbody EM 85
models 90, 91
organizing centers 85
stabilization 106–14
azide and colchicine effects 113
concentration dependence 11
cytoskeleton 112
taxol 106–14
taxol congeners 110
taxol binding 99–106
taxol effects and structure 96–9

Neurotransmitters
and embryogenesis 23–52
prenervous systems 24, 25
information lacking 51
roles 49, 50
Nifedipine effects 272 *see also* calcium antagonists

Ornithine decarboxylase inhibition 248

Penicillin binding proteins
bifunctional 355
fractionation, *Staphylococcus aureus* 357
β-lactam 354
peptidoglycan biosynthesis enzymes 351–8
purification 356, 357
sources and enzymic activities 352
Peptidoglycan 327–60
acetylation and deacetylation 358, 359

antibodies and synthesis 330, 344, 345
biosynthesis pathway 328–60
mutants 332, 333
cross-bridge peptide synthesis 338–40, 345–51
D-amino acids 339, 340
glycan chain elongation 341, 342
lipid cycle 333–45
synthesis of carriers 334, 335
nucleotide-linked precursors 330–3
antibiotic effects 330
regulation 332
pentapeptide modification 337, 338
phospho-*N*-acetylmuramoylpentapeptide translocase 335–7
polymeric intermediates 342–4
regulation of synthesis 359, 360
structure 327–9
and bacteria 329
transpeptidation 345–51
direction 350, 351
gram-negatives 347
in vitro 346–50
Pharmacokinetics
cytosine arabinoside 210–12
tamoxifen 161–3
Platinum chemistry 297 *see also cis*-diammine-dichloroplatinum
Podophyllotoxin structure 92
Polyamine biosynthesis
inhibitors 247–9
structure 248
pathway 247
Pyrazolopyrimidines, structures 244, 245

Receptors, estrogen
rat uterus cytosol 139
tamoxifen interaction 134, 135, 138
Receptors, sea urchin embryogenesis 39

Sinefungin structure 245, 246
Superoxide dismutase inhibitors 250, 251

Tamoxifen 127–87
antiestrogen effect 164, 165
assay procedures 159, 161
blood concentrations 161, 162
males 170
postmenopause 169, 170
premenopause 168, 169
breast cancer 171–9
breast disease, benign 185, 186
cellular accumulation 130–4
compounds affecting 134
derivative structures 137
distribution 160, 161
fertility 151, 152
gene transcription 142, 143
gonadotropin release 150, 151
half-life 162, 163
infertility 184, 185
lactation 186
liver effects 151
male effects 152, 153
metabolic pathways 159
metabolites, pharmacological activity 163, 164
nuclear translocation 140
ovulation induction 185
pharmacology and animal species 143–6
pituitary gland effects 148
prolactin release 148, 150, 151
purine nucleoside analogs 242, 243
pyrimidine nucleoside analogs structure 243
rat tissue radioactivity 133
rat uterus cytosol 136, 137
receptor binding 134–9
nuclear acceptor sites 141, 142
nuclear and agonists 140, 141
status in breast cancer 173
receptor replenishment 142
side-effects 165–7, 174
small intestine cytosine arabinoside effects 226–31
structural modification and receptor binding 135–9
structure 127, 160
metabolites 160
synthesis and isomers 129, 130
teratology 167
toxicity 165–7
tumor concentrations 162
tumor model effects 153–9
tumor treatment 171–84
and cytotoxic chemotherapy 176–8
endocrine therapy combined 176
endocrine therapy comparison 174, 175, 177
uterus actions 146–9, 170, 171
vaginal effects 171
Taxol
antimitotic effects 83–119
cancer therapy potential 118, 119
congeners, structural formulae 109
in vitro effects 95, 96
mechanisms of action in cells 116, 117
microtubule arrays 96–9
microtubule assembly 83–91
microtubule binding
bundle formation and ATP 104, 105
calcium 101
erythrocytes 103
inhibitors affecting 105
kinetics 99
reversible 100
temperature 102
model of action in cells 117, 118
structure 92
tubulin-microtubule effects 114, 115
Thymidylate synthetase 66, 67
Transformation, human cell; DNA lesions and repair 395–406
Trypanocides
nucleoside analogs 243
polyaromatic structures 242
pyrazolopyrimidine structures 244, 245
targets 246
Trypanosomes
glycoprotein biosynthesis 249
macromolecule synthesis inhibitors 239–51
nucleic acid synthesis inhibitors 239–41
polyamine synthesis inhibitors 247–9
purine metabolism 240
pyridine metabolism 240
threonine catabolism inhibitors 249
Tryptamine, sea urchin binding 28, 29
Tubulin
calcium interaction 91
colchicine interaction 93–5
immunofluorescence 86, 87
Vinca alkaloids 91–3
Tumor models and tamoxifen 153–9

OL.
25
984

breast cancer 157, 158
carcinogen-induced rat mammary 153–5
DMBA-induced rat endometrial 156
hamster renal 157
irradiation-induced rat mammary 155
mouse mammary 156
rat prostate 156
transplantable rat mammary 155
Tumor treatment and tamoxifen 171–84
breast cancer, advanced 171–9
adjuvant 179–81
dose-response 172
hormone receptors 173
male 179
previous therapy 173
tamoxifen response 174, 175
endometrial carcinoma 181, 182
melanoma 183, 184
ovarian carcinoma 182
pituitary 184
prostate carcinoma 182
renal carcinoma 182, 183
Tunicamycin structure 250

Verapamil effects 272 *see also* calcium antagonists

OL.
25
984